Hello Health Advance Shareholders!

In the new spirit of transparency and accountability to HADV shareholders, a few comments about next steps.

As your new President, my absolute top priority is to rectify a 3-year old problem – a lack of public filings and disclosure by former management.  This has caused a depressed share price and prevented shareholders from knowing what actions were being taken by former management, or even who management was.  A review of all corporate actions since the last filing is underway with the purpose of ensuring our reporting integrity.  This will be rooted in tracking all steps taken since the last date of disclosure compliance, and by whom, and establishing the compliance of such actions with regulations pertaining to same.  This is an administrative matter for the present management and will not impair business progress – in fact, our dedication to shareholder disclosure is now enabling Health Advance business progress, at last.

The company will be announcing at some time in April 2021 its new plans for business activity to advance Health Advance shareholder value, and discussing the new investments into Health Advance that will make this possible.

This attention to reporting has come in the proverbial “nick of time”.   On September 16, 2020, one year after issuing proposed rules, the Securities and Exchange Commission adopted final rules amending Securities Exchange Act (“Exchange Act”) Rule 15c2-11. The amendment is to enhance retail protection where there was little or no current and publicly available information about a company.  This was necessary because it is difficult for a “retail investor’ or other market participant to evaluate a company and the risks involved in purchasing or selling its publicly quoted securities without adequate public information.  Often in such cases, private deals take place between company management and 3rd parties to acquire shares at a severe discount to prevailing market prices, sometimes even in attempted control block changes, without any public notice.  In such cases, undisclosed sellers and buyers gain inordinate personal advantage by exploiting the lack of knowledge of such transactions by retail investors, regulators and investment industry personnel.  In some cases, such failure to make any public disclosure is deliberate, flagrant and conceals criminal liability.   Companies that would not have become compliant in these new SEC disclosure obligations would be subject to SEC cancellation of their quotation/trading rights, beginning in June 2021. The SEC believes that these amendments will preserve the integrity of the OTC market, and will promote capital formation for issuers that provide current and publicly available information to investors.  The grace period for companies to comply to these new regulations is almost over.

Fortunately for Health Advance shareholders, your company’s new management is immersed in the process of bringing filings up-to-date by the end of May 2021 under the OTC Alternative Reporting guidelines, following which the company expects to be awarded the Pink Current Information designation by OTC Markets.

Equally important,  your new Health Advance management is enthusiastic about the benefits that will soon flow to you, our shareholders, from the company’s renewed focus on ambitious and productive business activity,  as well as from the restored integrity of its shareholder relationships.

All Health Advance shareholders are invited to correspond with the company about any matter of interest to them.  When doing so, please include proof of valid, current share ownership to be compared to the company’s records for the purpose of correspondence.   Your new management is eager to foster a respectful, open and accountable relationship with Health Advance shareholders, effective immediately, and to delivering to you productive Health Advance business operations shortly.

Sincerely,
Larry McLachlin, President
HEALTH ADVANCE, INC.